Clinical trials - DiabetesontheNet

This site is intended for healthcare professionals only

Clinical trials

Filter:

Diabetes Distilled: The STEP trial programme – semaglutide and weight reduction

Weight reduction in people with type 2 diabetes demonstrated with semaglutide.

Editorial: Plotting a course through the diabetes guidance in a changed world

Making sense of the treatment recommendations in uncertain times.

Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) trial: benefits of involvement for patients and clinicians

ADA from home!

Practical messages for primary care practice from the American Diabetes Association's annual conference.

News from the 2020 ADA conference

Breaking news stories from a primary care perspective.

DAPA-CKD trial: Phase 3 stopped early after showing efficacy for CKD

AstraZeneca has announced that the phase 3 DAPA-CKD (Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease) trial will be stopped early following a recommendation from an independent data monitoring committee (DMC) based on its determination of overwhelming efficacy

GLP-1 receptor agonists significantly improve CV outcomes

GLP-1 receptor agonists have a wide range of benefits

Canagliflozin effective in primary and secondary prevention of CV outcomes

Diabetes Distilled: Controversial metformin recommendations in new ESC guidance

European guidance reflects new evidence on risk management in diabetes and pre-diabetes.

Renoprotection for patients with diabetes and kidney disease

Canagliflozin is cardioprotective in diabetic kidney disease

Semaglutide reduces cardiovascular risk in type 2 diabetes

Lowering LDL-cholesterol reduces CV event risk in diabetic dyslipidaemia

Updates from the 2019 ADA meeting

News of the most important trial results for diabetes care from the 79^th Scientific Sessions of the American Diabetes Association.

Renal trials, sex disparities in treatment, amputation and ADA nutrition guidelines

A round-up of the latest evidence and developments that will influence diabetes care.

Editorial: Reducing the type 2 diabetes epidemic: Where can we make most impact?

Pam Brown, Editor-in-Chief, considers how primary care can best address the type 2 diabetes epidemic, and looks at new evidence from CREDENCE on preventing the progression of diabetic kidney disease.

Canagliflozin provides renoprotection in type 2 diabetes with kidney disease

In this trial, investigators randomised patients with type 2 diabetes and kidney disease who had full renin–angiotensin–aldosterone system blockade to receive canagliflozin 100mg or placebo. Patients who took canagliflozin were 30% less likely than the placebo group to develop renal failure or die from either renal failure or cardiovascular disease. Their risk of renal failure or death fromrenal causes was reduced by 34%, and the risk of hospitalisation forheart failure or death due to cardiac causes decreased by 31%. Absolute risk reduction was 4.5%, translating into a number needed to treat of 22 over 2.5 years.

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;